Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo
about
Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsIn vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cellsSynergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2.The 26S proteasome complex: an attractive target for cancer therapyThiostrepton is an inducer of oxidative and proteotoxic stress that impairs viability of human melanoma cells but not primary melanocytesProteasome inhibitors in mantle cell lymphomaPLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivoThe Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma.New proteasome inhibitors in myeloma.HDAC inhibitor-based therapies: can we interpret the code?Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.Novel agents in mantle cell lymphoma.Histone Deacetylase Inhibitors as Anticancer Drugs.How do tumor cells respond to HDAC inhibition?Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.Targeting oxidative stress in embryonal rhabdomyosarcoma.Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors.Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action.
P2860
Q33959993-AB0BB634-905D-44F2-8C71-CC6EF6D69468Q33983255-12CA5420-BECD-4813-AA4E-B30A9C9E3783Q34000612-A96D92F8-9427-4760-92E0-5E93E64C5DB0Q34218976-C9B5C4E7-04E0-4B84-A1B1-F738609FC70AQ35007061-BA35124D-F5AC-42CB-B3E3-95F88AB46697Q35592352-25C0750F-5DEE-4129-A44A-BE30CED3628AQ35624079-416D1E71-E78A-4311-9273-5A646E4C9A0EQ35823218-27F97495-FF55-49A4-9AFB-F50A67AC9933Q36028745-BEB9E879-F2D2-49EC-9884-98ECEF2F5744Q36544946-42C3F88D-376D-4434-B870-F7450427625BQ36578084-41598B6D-E393-4A74-9710-4010C083A4E0Q36697045-A090469F-7C1D-4A74-88F8-65FA199FC858Q37084564-63E58AC6-4313-4BB7-944A-D30926EE463EQ37301751-26E3C763-10DD-4514-966E-E156247BDCAFQ38052079-E0ABF140-B09B-4F3A-ACA7-6BBE5B786AD8Q38058971-99E1C581-6A14-405B-B27A-54F1E9E0D6ABQ38079578-A4EC7E49-C5E3-4095-9753-45DC4E9F2185Q38240733-844289F6-BF3A-41E7-8E9B-F2B884E96749Q38516704-221C570F-2369-468D-A819-188517504112Q38696932-56E833FF-740A-4A7C-AE31-5FF5FA3A7BE5Q38817005-730722E2-0011-47BC-9631-D0743821EE70Q38906418-C465C688-7682-4A59-8C29-9CE517D3631CQ38986185-4D8AD915-2C18-4166-8B67-6CB25354602DQ39289240-3E2EA80C-2258-4451-84AC-4496A434D65CQ41896211-63825368-C280-4174-AB53-46A08E51DFF4Q52869149-51F42F26-C1F4-4499-893D-0C2454109A75Q53143241-C4585C3E-F4A6-4E0B-B740-C6372AF97A12
P2860
Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Carfilzomib interacts synergis ...... oma cells in vitro and in vivo
@ast
Carfilzomib interacts synergis ...... oma cells in vitro and in vivo
@en
type
label
Carfilzomib interacts synergis ...... oma cells in vitro and in vivo
@ast
Carfilzomib interacts synergis ...... oma cells in vitro and in vivo
@en
prefLabel
Carfilzomib interacts synergis ...... oma cells in vitro and in vivo
@ast
Carfilzomib interacts synergis ...... oma cells in vitro and in vivo
@en
P2093
P2860
P1476
Carfilzomib interacts synergis ...... oma cells in vitro and in vivo
@en
P2093
Dmitry Lembersky
Elisa Attkisson
Girija Dasmahapatra
Jonathan W Friedberg
Minkyeong P Son
Richard I Fisher
Steven Grant
P2860
P304
P356
10.1158/1535-7163.MCT-10-1108
P50
P577
2011-07-12T00:00:00Z